UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
10/551,189	09/29/2005	Falko Skrabal	66376-365-7	1869	
	S9 7590 04/30/2007 KEMA GOSSETT PLLC EXAMINER				
FRANKLIN SQUARE, THIRD FLOOR WEST 1300 I STREET, NW WASHINGTON, DC 20005			NATNITHITHADHA, NAVIN		
			ART UNIT	PAPER NUMBER	
		•			
			MAIL DATE	DELIVERY MODE	
		·	04/30/2007	PAPER	

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

		Application No.	Applicant(s)	
		10/551,189	SKRABAL ET AL.	
	Office Action Summary	Examiner	Art Unit	
		Navin Natnithithadha	3735	
	The MAILING DATE of this communication	appears on the cover sheet wi	th the correspondence address	
Period fo	• •			
WHIC - Exte after - If NO - Failu Any	HORTENED STATUTORY PERIOD FOR RECHEVER IS LONGER, FROM THE MAILING ensions of time may be available under the provisions of 37 CF r SIX (6) MONTHS from the mailing date of this communication of period for reply is specified above, the maximum statutory peure to reply within the set or extended period for reply will, by some reply received by the Office later than three months after the need patent term adjustment. See 37 CFR 1.704(b).	G DATE OF THIS COMMUNIC R 1.136(a). In no event, however, may a re t. briod will apply and will expire SIX (6) MON tatute, cause the application to become AB	CATION.  eply be timely filed  THS from the mailing date of this communication.  ANDONED (35 U.S.C. § 133).	
Status				
1)⊠	Responsive to communication(s) filed on 6	18 June 2006.		
2a) <u></u>	)☐ This action is <b>FINAL</b> . 2b)⊠ This action is non-final.			
3)	Since this application is in condition for allo	owance <sub>\</sub> except for formal matte	ers, prosecution as to the merits is	
	closed in accordance with the practice und	ler <i>Ex parte Quayle</i> , 1935 C.D	. 11, 453 O.G. 213.	
Disposit	tion of Claims			
4)🛛	Claim(s) 27-40 is/are pending in the applic	ation.		
,	4a) Of the above claim(s) is/are with			
5)[	Claim(s) is/are allowed.			
6)⊠	Claim(s) 27-40 is/are rejected.			
•	Claim(s) is/are objected to.			
8)	Claim(s) are subject to restriction ar	nd/or election requirement.		
Applicat	tion Papers			
9)🖂	The specification is objected to by the Exar	niner.		
10)	The drawing(s) filed on is/are: a)	accepted or b) objected to I	by the Examiner.	
	Applicant may not request that any objection to	the drawing(s) be held in abeyan	ice. See 37 CFR 1.85(a).	
_	Replacement drawing sheet(s) including the co	•	• •	
11)	The oath or declaration is objected to by the	e Examiner. Note the attached	Office Action or form PTO-152.	
Priority	under 35 U.S.C. § 119			
12)	Acknowledgment is made of a claim for for	eign priority under 35 U.S.C. §	119(a)-(d) or (f).	
a)	)			
	1. Certified copies of the priority docum			
	2. Certified copies of the priority docum			
	3. Copies of the certified copies of the		received in this National Stage	
* *	application from the International Bu	, , , , , , , , , , , , , , , , , , , ,	received	
7 ;	See the attached detailed Office action for a	nist of the certified copies not	IECEIVEU.	
Attachmer	nt(s)			

U.S. Patent and Trademark Office PTOL-326 (Rev. 08-06)

1) X Notice of References Cited (PTO-892)

2) Notice of Draftsperson's Patent Drawing Review (PTO-948)

3) Information Disclosure Statement(s) (PTO/SB/08)
Paper No(s)/Mail Date 20060608.

4) Interview Summary (PTO-413)
Paper No(s)/Mail Date.

6) Other: \_\_\_\_\_

5) Notice of Informal Patent Application

### **DETAILED ACTION**

### Response to Amendment

1. Claims 1-26 have been cancelled. Claims 27-40 have been added. Claims 27-40 are pending.

#### Oath/Declaration

2. The oath or declaration is defective. A new oath or declaration in compliance with 37 CFR 1.67(a) identifying this application by application number and filing date is required. See MPEP §§ 602.01 and 602.02.

The oath or declaration is defective because:

It does not state that the person making the oath or declaration acknowledges the duty to disclose to the Office all information known to the person to be material to patentability as defined in 37 CFR 1.56.

Applicant's Declaration incorrectly states, "I acknowledge the duty to disclose information which is material to the examination of this application in accordance with Title 37, Code of Federal Regulations, § 1.56(a)."

### Information Disclosure Statement

3. The information disclosure statement filed 08 June 2006 fails to comply with 37 CFR 1.98(a)(3) because it does not include a concise explanation of the relevance, as it is presently understood by the individual designated in 37 CFR 1.56(c) most knowledgeable about the content of the information, of each patent listed that is not in

Art Unit: 3735

the English language. It has been placed in the application file, but the information referred to therein has not been considered.

# **Priority**

4. Acknowledgment is made of applicant's claim for priority under 35 U.S.C. 119(a)-(d) based upon an application filed in Austria on 04 January 2003.

Receipt is acknowledged of papers submitted under 35 U.S.C. 119(a)-(d), which papers have been placed of record in the file.

### **Drawings**

5. The subject matter of this application admits of illustration by a drawing to facilitate understanding of the invention. Applicant is required to furnish a drawing under 37 CFR 1.81(c). No new matter may be introduced in the required drawing. Each drawing sheet submitted after the filing date of an application must be labeled in the top margin as either "Replacement Sheet" or "New Sheet" pursuant to 37 CFR 1.121(d).

## Specification

6. Applicant is reminded of the proper language and format for an abstract of the disclosure.

The abstract should be in narrative form and generally limited to a single paragraph on a separate sheet within the range of 50 to 150 words. It is important that the abstract not exceed 150 words in length since the space provided for the abstract on the computer tape used by the printer is limited. The form and legal phraseology often used in patent claims, such as "means" and "said," should be avoided. The

Application/Control Number: 10/551,189 Page 4

Art Unit: 3735

abstract should describe the disclosure sufficiently to assist readers in deciding whether there is a need for consulting the full patent text for details.

The language should be clear and concise and should not repeat information given in the title. It should avoid using phrases which can be implied, such as, "The disclosure concerns," "The disclosure defined by this invention," "The disclosure describes," etc.

The abstract of the disclosure does not commence on a separate sheet in accordance with 37 CFR 1.52(b)(4). A new abstract of the disclosure is required and must be presented on a separate sheet, apart from any other text.

7. The following guidelines illustrate the preferred layout for the specification of a utility application. These guidelines are suggested for the applicant's use.

### Arrangement of the Specification

As provided in 37 CFR 1.77(b), the specification of a utility application should include the following sections in order. Each of the lettered items should appear in upper case, without underlining or bold type, as a section heading. If no text follows the section heading, the phrase "Not Applicable" should follow the section heading:

- (a) TITLE OF THE INVENTION.
- (b) CROSS-REFERENCE TO RELATED APPLICATIONS.
- (c) STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH OR DEVELOPMENT.
- (d) THE NAMES OF THE PARTIES TO A JOINT RESEARCH AGREEMENT.
- (e) INCORPORATION-BY-REFERENCE OF MATERIAL SUBMITTED ON A COMPACT DISC.
- (f) BACKGROUND OF THE INVENTION.
  - (1) Field of the Invention.
  - (2) Description of Related Art including information disclosed under 37 CFR 1.97 and 1.98.
- (g) BRIEF SUMMARY OF THE INVENTION.
- (h) BRIEF DESCRIPTION OF THE SEVERAL VIEWS OF THE DRAWING(S).
- (i) DETAILED DESCRIPTION OF THE INVENTION.
- (j) CLAIM OR CLAIMS (commencing on a separate sheet).
- (k) ABSTRACT OF THE DISCLOSURE (commencing on a separate sheet).
- (I) SEQUENCE LISTING (See MPEP § 2424 and 37 CFR 1.821-1.825. A "Sequence Listing" is required on paper if the application discloses a nucleotide or amino acid sequence as defined in 37 CFR 1.821(a) and if

Art Unit: 3735

the required "Sequence Listing" is not submitted as an electronic document on compact disc).

8. The disclosure is objected to because of the following informalities:

The Specification is missing section headings. Appropriate correction is required.

## Claim Rejections - 35 USC § 112

The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

9. Claims 27-34 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

The claimed method is indefinite because the steps of the method are not clearly defined. The Examiner suggests affirmatively stating each method step by inserting "comprising", indentation, and colons.

10. Claims 35-40 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

The claimed device is indefinite because the elements of the device, e.g. "a first plethysmographic sensor device," "a controlling and adjusting device," a first pressure measuring chamber," etc., are not clearly defined. The Examiner suggests affirmatively stating each element of the device by inserting "comprising", indentation, and colons.

Art Unit: 3735

## Claim Rejections - 35 USC § 102

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless -

(e) the invention was described in (1) an application for patent, published under section 122(b), by another filed in the United States before the invention by the applicant for patent or (2) a patent granted on an application for patent by another filed in the United States before the invention by the applicant for patent, except that an international application filed under the treaty defined in section 351(a) shall have the effects for purposes of this subsection of an application filed in the United States only if the international application designated the United States and was published under Article 21(2) of such treaty in the English language.

11. Claims 27-40 are rejected under 35 U.S.C. 102(e) as being anticipated by Ogura et al, US 6,796,946 B2 ("Ogura").

<u>Claims 35-40</u>: Ogura teaches a device 10 for the continuous, non-invasive measurement of blood pressure based on the principle of the unloaded arterial wall (see Abstract), comprising:

at least one first pressure cuff (ankle cuff) 20 and one second pressure cuff (upper-arm cuff) 40 of identical or comparable size, the first pressure cuff 20 and the second pressure cuff 40 are attached on at least one first body part or body region (ankle) 12 and one second body part or body region (upper-arm) 14, respectively, containing an artery of identical or comparable size (see fig. 1);

wherein the first pressure cuff and the second pressure cuff include first and second inflatable pressure measuring chambers (rubber bag, see col. 6, Il. 54);

wherein the first pressure cuff 40 being provided with a first plethysmographic sensor device (photoelectric-pulse-wave sensor, see col. 7, II. 46-59) 56, which is positioned at the distal end of a toe;

Application/Control Number

Art Unit: 3735

wherein the first pleythysmographic sensor device 56 connected to a controlling and adjusting device (control device) 36, which controls the pressure in the pressure measuring chamber (ankle rubber bag) of the first pressure cuff 20 using the measuring signal of the plethysmographic sensor device 56 (see fig. 1);

wherein the pressure measuring chamber of the first pressure cuff 20 is connected to a pressure sensor 24 to obtain a pressure measuring signal SP1 (see fig. 1);

wherein the pressure measuring chamber (upper-arm rubber bag) of the second pressure cuff 40 is configured as a reference pressure chamber, which is controlled simultaneously with and independently of the pressure measuring chamber of the first pressure cuff 20 (see fig. 3); and

wherein the pressure measuring chamber of the first pressure cuff 20 and the reference pressure chamber of the second pressure cuff 40 each have separate inlet valves 26 and outlet valves 44 and each connected by separate pressure lines, the pressure in the reference pressure chamber being controlled via the controlling and adjusting device 56 in accordance with a preselectable pressure function (see figs. 5 and 6).

Claims 27-34: Ogura teaches a method for the continuous, non-invasive measurement of blood pressure based on the principle of the unloaded arterial wall, where on at least one first (ankle) 12 and one second (upper-arm) 14 body part or body region, each containing an artery of identical or comparable size, there is positioned a first 20 and a second 40 pressure cuff of identical or comparable size with a first and a

Art Unit: 3735

second inflatable pressure measuring chamber (ankle and upper-arm rubber bags), the pressure in the first pressure measuring chamber being controlled in dependence of the measurement signal of a plethysmographic sensor device in such a way that the amplitude of the plethysmographic measurement signal is minimized (see fig. 5), and a pressure measuring signal being obtained from the first pressure measurement chamber, wherein the second pressure measuring chamber is operated as a reference pressure chamber independently of the first pressure measuring chamber (see fig. 3), and wherein the pressure in the reference pressure chamber is controlled in accordance with a preselectable pressure function (see fig. 6), a reference signal being obtained simultaneously with the pressure measuring signal, and the reference signal is used in the interpretation of the pressure measuring signal (see fig. 3), wherein the setpoint (ABI index) of the pressure measuring signal is continuously monitored and/or adjusted by means of the reference signal (see col. 10, II. 7-43), wherein a physiological or pathological change of the pressure measuring signal is inferred from a change of the mean pressure and/or the amplitude of the pressure measuring signal and a shift of the amplitude maximum of the reference signal or the reference pressure signal in the same direction (ABI index is used to determine the presence of arteriosclerosis).

#### **Conclusion**

12. The prior art made of record and not relied upon is considered pertinent to applicant's disclosure.

Art Unit: 3735

The other prior art references cited in the PTO-892 teach subject matter related to the Applicant's claims. The Examiner suggests reviewing these patents before responding to the present Office Action.

13. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Navin Natnithithadha whose telephone number is (571) 272-4732. The examiner can normally be reached on Monday-Friday, 8:00-4:00.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Charles Marmor, II, can be reached on (571) 272-4730. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

Navin Natnithithadha Patent Examiner

Milled

Art Unit 3735